Biotech Investors: Believing the Dream, Rewarding Phase III IPOs
This article was originally published in Start Up
Executive SummaryValuation Watch: our analysis of US biotech companies that have gone public in the 2003-04 window shows that having a late-stage development project offers private investors the best step-ups.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.